Sorrento Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 949
- Market Cap
- -
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19
Phase 1
Completed
- Conditions
- Covid19
- Interventions
- Biological: PSC-04
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04486001
- Locations
- 🇺🇸
Fresno Community Hospital, Fresno, California, United States
Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19
Phase 1
Withdrawn
- Conditions
- Covid-19
- Interventions
- Biological: COVI-GUARDDrug: PlaceboOther: Standard of Care
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04454398
Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04440007
- Locations
- 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Teradan Clinical Trials, Brandon, Florida, United States
🇺🇸Quality Clinical Research, Omaha, Nebraska, United States
Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed
Phase 3
Withdrawn
- Conditions
- Osteoarthritis, KneeKnee Pain ChronicOsteo Arthritis Knee
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04386980
Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis
Phase 1
Recruiting
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- Biological: STI-6129
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04316442
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Barbara Ann Karmanos Cancer Institute Wertz Clinic, Detroit, Michigan, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Phase 1
Recruiting
- Conditions
- Mycosis Fungoides
- Interventions
- Combination Product: Pembrolizumab administered using the Sofusa® DoseConnect™
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04118868
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
A Phase 3 Study to Evaluate the Efficacy and Safety of Resiniferatoxin for Pain Due to Osteoarthritis of the Knee
Phase 3
Withdrawn
- Conditions
- Osteoarthritis, KneeKnee Pain Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04044742
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
Phase 2
Withdrawn
- Conditions
- Malignant Tumor of Pancreas Metastatic to Liver
- Interventions
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT04037241
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Phase 2
Withdrawn
- Conditions
- Extranodal NK T Cell Lymphoma, NasalDiffuse Large B Cell LymphomaBiliary Tract CancerPeripheral T Cell Lymphoma
- Interventions
- Biological: STI-3031
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2023-05-01
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT03999658
Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases
Phase 1
Terminated
- Conditions
- Metastatic Pancreatic Carcinoma
- Interventions
- Biological: CAR2 Anti-CEA CAR-T cells
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03818165
- Locations
- 🇺🇸
Roger Williams Medical Center, Providence, Rhode Island, United States
© Copyright 2025. All Rights Reserved by MedPath